Evidence map›Paper›PMID 33147726›Full record

ArticleVaccines2020

Multifunctional Monoclonal Antibody Targeting

Wesley Hebert, Antonio DiGiandomenico, Michael Zegans

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Frontiers in cellular and infection microbiology · 2023
    Review
  2. Article
  3. Ocular Delivery of Predatory Bacteria with Cryomicroneedles Against Eye Infection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Article
  4. Systemic diseases and the cornea.Experimental eye research · 2021
    Review
  5. Non-antibiotic management of bacterial keratitis.Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Wesley HebertDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth School, Hanover, NH 03756, USA.
Antonio DiGiandomenicoMicrobial Sciences, BioPharmaceuticals R&D, AstraZeneca, One MedImmune Way, Gaithersburg, MD 20878, USA.
Michael ZegansDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth School, Hanover, NH 03756, USA.
Dartmouth College · USAstraZeneca (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A worrisome trend in the study and treatment of infectious disease noted in recent years is the increase in multidrug resistant strains of bacteria concurrent with a scarcity of new antimicrobial agents to counteract this rise. This is particularly true amongst bacteria within the

Indexed as

antibodyantimicrobialbacterial keratitiscorneaimmunotherapymicrobial keratitispseudomonas aeruginosa

Identifiers

PMID33147726
PMCPMC7712430
OpenAlexW3097264516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.